Performance of Upper Limb

Capricor's Duchenne vote is a verdict on design choices made years before the data

An FDA panel voted against deramiocel on a secondary cardiac endpoint measured partly in boys whose hearts were still stable. The agency then pointed the sponsor back to its primary endpoint.